Pfizer submits data for US approval of third dose

Pfizer and BioNTech on Monday submitted preliminary clinical data to US health authorities as part of their effort to seek authorization for a third dose of their COVID-19 vaccine for all Americans, AFP reports.

The two companies presented the results of their Phase One trial that evaluated the safety and efficacy of a third shot.